ERCC2 and metabolic dysfunction-associated steatohepatitis: BRD-K93672499 can be considered a multitarget therapeutic strategy targeting ERCC2 and FOXC2 for the treatment of NASH.<h4>Conclusion</h4>Our study first deciphered the m5C in predictive and therapeutic potential for NASH patients, which gains more insight into their personalized and precision medicine.